VERVE-102 cut LDL cholesterol by about 62% in an early trial, most helpful for those with family history, but more diverse ...

Verve-102 uses gene editing to target PCSK9 and lower LDL cholesterol after one infusion, showing promising early results but ...

Gene therapy represents one of medicine’s most ambitious attempts to treat disease at its root cause by altering the genetic code itself. The approach works by recovering the functions of critical ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...

Researchers used CRISPR to remove the CD33 protein from donor stem cells, protecting healthy blood cells from therapies that target leukemia. ・In a 30-patient trial, the edited cells rebuilt blood ...

Like a delivery driver navigating crowded city streets, a gene-therapy-toting lipid nanoparticle faces a gauntlet of potential detours on its journey toward a cell's nucleus. First, there's entering ...

Sickle-cell disease and β-thalassemia are inherited blood disorders that are caused by mutations in the HBB gene (encoding a component of adult hemoglobin) and are characterized by severe, lifelong ...

Gene-editing techniques such as CRISPR-Cas9 have many uses in the area of food and agriculture. They can combat persistent drought and disease, and improve the colour and nutritional content of food ...

What if you could precisely change the genome of a pre-implantation human embryo and then safely use that embryo to try to generate a healthier person? It’s a wild idea, but one that technology over ...

Two undisclosed deaths in Chinese gene-editing trials renew concerns about trial oversight, safety reporting, and ...

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.

After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome Biosciences is making cuts. “Despite our clear scientific progress, investor sentiment has shifted dramatically ...